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Abstract Enterococci are among the leading pathogens isolated in hospital-acquired infections.  Current antimi-
crobial options for vancomycin-resistant enterococci (VRE) are limited.  Prior data suggests that daptomycin > 
6mg/kg/day may be used to treat enterococcal infections.  We retrospectively evaluated the effectiveness and safety 
of high-dose daptomycin (HD-daptomycin) therapy (> 6 mg/kg) in a multicenter cohort of adult patients with enter-
ococcal infections to describe the characteristics and outcomes.  Two-hundred and forty-five patients were evaluated. 
Enterococcus faecium was identified in 175 (71%), followed by 49 (20%) Enterococcus faecalis and 21 (9%) Enter-
ococcus spp., overall 204 (83%) were VRE.  Enterococcal infections included bacteremia (173, 71%), intra-
abdominal (35, 14%) and bone/joint (25, 10%).  The median dose and duration of HD-daptomycin was 8.2 
mg/kg/day (IQR 7.7-9.7) and 10 days (IQR 6-15), respectively.  Overall clinical success rate was 89% (193/218) and 
microbiological eradication was observed in 93% (177/191) of patients.  The median time to clearance of blood cul-
tures on HD-daptomycin was 3 days (IQR 2-5).  Thirty-day all cause mortality rate was 27% and 5 (2%) patients 
developed daptomycin nonsusceptible enterococcal strains while on HD-daptomycin. Seven patients (3%) had crea-
tine phosphokinase (CPK) elevation, yet no HD-daptomycin regimen was discontinued due to an elevated CPK and 
all patients were asymptomatic.  Overall, there was a high frequency of clinical success and microbiological eradica-
tion in patients treated with HD-daptomycin for enterococcal infections, even in patients with complicated and diffi-
cult to treat infections. No adverse event-related discontinuation of HD-daptomycin was noted.  HD-daptomycin 
may be an option for the treatment of enterococcal infections. 
 






Infections with multidrug-resistant Gram-positive organ-
isms are becoming highly prevalent(1). In particular, van-
comycin-resistant enterococci (VRE) infections are diffi-
cult to treat and have been associated with multiple patient 
comorbidities and prolonged duration of hospitalization, 
with the predominant pathogens being Enterococcus fae-
calis and Enterococcus faecium(2, 3).  In fact, Enterococ-
cus spp. Are the second most common nosocomial blood-
stream pathogen isolate in the United States(4), with VRE 
frequencies in intensive care units (ICU) exceeding 30%(5).  
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Unfortunately, there are limited effective therapeutic op-
tions for VRE infections. 
Currently, linezolid is approved by the US Food and 
Drug Administration (FDA) for the treatment of VRE in-
fections; however, several limitations exist with this 
agent(6).  Studies evaluating linezolid for the treatment of 
VRE faecium bloodstream infection (BSI) have revealed 
clinical success frequency ranging from 58% to 78%(7, 8).  
However, reports of linezolid resistance have emerged in 
VRE, with an incidence as high as 20%(9).  Moreover, 
prolonged treatment with linezolid can lead to myelosup-
pression, including neutropenia, thrombocytopenia, and 
anemia, which are frequent comorbid conditions already 
present in many patients with VRE infections(6, 10).  Last-
ly, linezolid is bacteriostatic against enterococci(6) and in 
serious infections (e.g. prolonged VRE bacteremia specifi-
cally endocarditis) a bactericidal agent is preferred(11).  
 Daptomycin is a concentration-dependent bactericidal 
agent currently approved at 4 and 6 mg/kg daily for the 
treatment of skin and skin-structure infections (SSSIs) and 
Staphylococcus aureus bacteremia, respectively(12, 13). 
Both in-vivo and in-vitro studies have revealed that using 
higher dosages of daptomycin increased both the degree 
and speed of bactericidal activity due to its concentration-
dependent pharmacodynamic mechanism.   Further, high 
dosages can decrease the emergence of resistance in Staph-
ylococcus aureus(14).  Daptomycin possesses similar and 
potent activity against enterococci and is FDA approved 
for the treatment of SSSIs including those caused by van-
comycin-susceptible E. faecalis(15).  However, due to in-
trinsically lower susceptibility in enterococci compared to 
staphylococci, minimum inhibitory concentrations (MIC) 
tend to be at 2 mg/L suggesting larger doses of daptomycin 
(approximately 8 mg/kg daily) may be necessary to obtain 
similar kill ratios to staphylococci(16).  Currently, there are 
no clinical dosing recommendations for the use of dap-
tomycin against enterococci, and most dosages reported via 
case reports indicate that a median dose of 6 mg/kg is most 
frequently used(17, 18). The emergence of resistance in 
enterococci to daptomycin has been reported; notably, 
these patients have had complicated infections (e.g., oste-
omyelitis, medical device infections, endocarditis) and 
have been treated with daptomycin at dosages of 6 mg/kg 
or less(19). 
Several case reports, registries and small cohort stud-
ies have observed positive clinical outcomes and have sug-
gested the use of higher doses of daptomycin for entero-
coccal infections(20-23).  Gallagher and colleagues per-
formed a retrospective analysis of patients with VRE BSI 
treated with daptomycin and concluded that clinical suc-
cess was associated with a daptomycin dose of ≥ 6 mg/kg 
(aOR 7.29, 95%; CI 1.02-52.0)(24).  It is possible that 
higher dosages of daptomycin in VRE infections may im-
prove the efficacy of this agent and prevent the emergence 
of resistance during therapy.  Our previous multi-center 
observational study examining high-dose daptomycin for 
the treatment of infections caused by Gram-positive organ-
isms suggested that this approach may be both efficacious 
and safe(21).   However, staphylococci were the primary 
pathogens in that cohort; therefore, a focused evaluation of 
high-dose daptomycin in serious enterococcal infections 
was not possible.  The objective of the present study was to 
evaluate the safety and effectiveness of high-dose dap-
tomycin therapy (> 6 mg/kg by total body weight) in pa-
tients with enterococcal infections in a large multi-center 
cohort of patients. 
METHODS 
A multi-center, retrospective cohort was conducted from 
January 2005 to October 2012 and included adult patients 
treated with daptomycin at dosages of > 6 mg/kg (total 
body weight) and with documented infection with entero-
cocci.  The study population included patients > 18 years 
of age with enterococcal infections at any site who re-
ceived daptomycin > 6 mg/kg per dose for at least 3 con-
secutive days (≥ 72 hours).  Patients were excluded if they 
had a diagnosis of pneumonia or urinary tract infection in 
the absence of enterococcal bacteremia, or received any 
form of dialysis (e.g., hemodialysis, continuous ambulatory 
peritoneal dialysis, and continuous renal replacement ther-
apy).  Data were collected retrospectively using a standard-
ized, electronic tool to capture demographics (e.g., age, 
gender, weight, renal function), infection site, diagnosis, 
severity of illness at the initiation of high-dose daptomycin 
therapy as determined by APACHE II score, comorbid 
conditions, prior and concomitant antimicrobial use, surgi-
cal procedures within the previous 30 days, duration of 
therapy, length of hospital stay, 30-day mortality and over-
all clinical outcome as ascertained by the treating medical 
team.  Safety data was also collected using adverse event 
reporting in the medical record. 
 Clinical assessments were determined at the end 
of daptomycin therapy.  Safety and adverse events were 
evaluated in all patients, while effectiveness was only de-
termined in patients with adequate medical record docu-
mentation to determine clinical response.  Clinical out-
comes were characterized as follows: cure: clinical signs 
and symptoms resolved and/or no additional antibiotic 
therapy necessary, or infection cleared with negative cul-
tures reported at the end of daptomycin therapy; improved: 
partial resolution of clinical signs and symptoms and no 
additional antibiotic therapy necessary at the end of dap-
tomycin therapy; failure: inadequate response to daptomy-
cin therapy or resistant, worsening, or new/recurrent signs 
and symptoms or a positive culture reported at the end of 
therapy(20-22, 25).  Patients with non-evaluable outcomes 
were those for whom medical records did not contain all 
necessary information to determine response at the end of 
inpatient daptomycin therapy.  Additional clinical assess-
ments included the presence and duration of the following: 
fever (temperature > 38.30 C), leukocytosis (> 10 
cells/mm3), ICU admission, mechanical ventilation, posi-
tive blood culture (time from 1st positive blood culture to 
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Table 1 
Baseline demographic and clinical characteristics. 
Characteristics Median (IQR) or n (%)  n = 245 
Age, years 58 (49-65) 
APACHE II Score 9 (6-14) 
Weight, kilograms 76.2 (61.3-93.2) 
Creatinine Clearance 69 (43.6-97.3) 
Male 131 (53.5) 
Prior Hospitalization 207 (84.5) 
Prior Surgery 53 (23.3) 
Neutropenia 51 (20.8) 
Diabetes 87 (35.5) 
Renal Disease 48 (19.6) 
Liver Disease 38 (15.5) 
Solid Organ/BMT 48 (19.6) 
Chemotherapy and/or Radiation 53 (21.6) 
ICU admission 125 (51) 
Mechanical ventilation 85 (34.7) 
Antibiotic Exposure Prior Admission       Prior Vancomycin 108 (44.1) 
     Prior Daptomycin 13 (5.3) 
     Prior Linezolid 32 (13.1) 
Antibiotics Given Before High-Dose DAP*       Linezolid 57 (23.3) 
     VancomycinΔ 25 (10.2) 
     Low-Dose Daptomycin (≤ 6mg/kg) 11 (4.5) 
     Quinupristin/Dalfopristin 5 (2.0) 
     Tigecycline 3 (1.2) 
Types of Infections  
     Intra-abdominal 35 (14.3) 
     Bone or Joint 25 (10.2) 
     Skin or Wound 11 (4.5) 
     Meningitis 1 (0.4) 
     Bloodstream Infection 173 (70.6) 
           IV catheter 66 (38.2) 
           Endocarditis 15 (8.7) 
           Intra-abdominal 32 (18.5) 
           Skin or Wound 13 (7.5) 
           Urinary  10 (5.8) 
           Bone or Joint 5 (2.9) 
           Prosthetic Device 5 (2.9) 
           Unknown 27 (15.6) 
*Antibiotics given during hospitalization of enterococcal infection that has in-vitro activity 
against enterococci; Δevaluated in vancomycin-susceptible enterococci; BMT = bone marrow 
transplant; ICU = intensive care unit; DAP = daptomycin; IV = intravenous 
 
first day of 48 hours of negative cultures), site(s) of infec-
tion determined by the diagnosing practitioner’s discretion, 
with the exception of specific definitions for endocardi-
tis(26), osteomyelitis(27), and uncomplicated and compli-
cated bacteremia(13).  Duration of bacteremia was calcu-
lated as the number of days between the first positive blood 
culture and the first negative blood culture result.   
 Microbiological Assessment 
Microbiologic data were obtained from available culture 
data during hospitalization, except for patients with osteo-
myelitis where culture data may include those from outpa-
tient clinic visits, if available.  Microbiologic response was 
defined as organism eradication, organism persistence, or 
no follow-up culture data available.  Eradication was de-
fined as elimination of the organism while on high-dose 
daptomycin and persistence was defined as failure to eradi-
cate the organism at the end of high-dose daptomycin ther-
apy(21, 25).  Organism identification, local susceptibility 
data and baseline blood isolates were collected, if available, 
and evaluated for extended microbiological assessment and 
verification at a central research laboratory facility (Anti-
Infective Research Laboratory, Wayne State University).  
For these isolates, daptomycin and vancomycin suscepti-
bility testing were performed by broth microdilution (BMD) 
and by Etest according to Clinical Laboratory Standards 
Institute guidelines and manufacturer instructions (bi-
oMerieux, Durham, NC)(28), respectively.  If the isolate 
was not available, the susceptibility interpretation and 
methodology were recorded from the referring institution. 
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Table 2 
Baseline vancomycin and daptomycin minimum inhibitory concentration. 
  DAP MIC (mg/L) 
  0.25 0.38 0.5 1 1.5 2 3 4 8 
Enterococcus faecium            
VAN MIC 
(mg/L) 
≤4 -- -- -- 1 1 -- -- 1 -- 
16-Aug -- -- --    1 2 -- 
≥32 -- -- -- 8 6 38 11 53 1 
           Enterococcus faecalis          
VAN MIC 
(mg/L) 
≤4 -- -- 1 2 -- 1 -- -- -- 
16-Aug -- -- -- -- -- -- -- -- -- 
≥32 1 1 1 3 4 4 -- 2 -- 
           
Enterococcus spp.           
VAN MIC 
(mg/L) 
≤4 -- -- 1 -- -- -- -- -- -- 
16-Aug -- -- -- -- -- -- -- 1 -- 
≥32 1 -- -- 1 2 1 2 3 -- 
           
Total  2 1 3 15 13 44 14 62 1 n = 155 
VAN = vancomycin, DAP = daptomycin, MIC = minimum inhibitory concentration 
 
Safety Assessment 
All adverse events, including serious adverse events, were 
evaluated for all subjects who received at least one dose of 
daptomycin therapy.  Adverse events were recorded only if 
a direct causal relationship to daptomycin was suspected 
and documented in the patient’s medical chart by the pri-
mary team.  Creatine phosphokinase (CPK) levels were 
assessed by evaluating any abnormal value or change from 
baseline, if available.  CPK elevation was defined in previ-
ous literature based on 2 sequential measurements during 
the period after 3 doses to 3 days after therapy(29).  Pa-
tients with unexplained signs and symptoms of myopathy 
in conjunction with a CPK elevation ≥ 1000 IU/L (~ 5X 
ULN) or asymptomatic patients with CPK ≥ 2000 IU/L (> 
10X ULN) were reported in further detail(15). 
Statistical Analysis 
SPSS Statistics, version 20.0 (IBM SPSS Inc., Chicago, IL) 
was used to perform descriptive statistics including data 
frequencies and distributions for categorical data; median 
and interquartile range (IQR) for continuous data.  Dap-
tomycin dose and maximum observed CPK levels were 
analyzed for relationship by using the Spearman’s rank 
correlation.  In addition, various MIC testing methods (au-
tomated institutional MIC vs. BMD and Etest) were ana-
lyzed for relationship by using Spearman’s rank correlation.  
Clinical outcome was compared by Pearson’s chi-square in 
relation to daptomycin MIC groups (≤ 2 mg/L versus > 2 
mg/L). 
RESULTS 
A total of 245 patients with enterococcal infections re-
ceived high-dose daptomycin during the time period stud-
ied.  Demographic and clinical characteristics of the pa-
tients are presented in Table 1. A total of 173 patients 
(70.6%) had a positive blood culture.  Among BSI patients, 
97 (56.1%) had complicated bacteremia and 76 (43.9%) 
had uncomplicated bacteremia.  Concomitant site of BSI 
along with the other types of infections are displayed in 
Table 1.  Two hundred twenty-one (90.2%) patients were 
given at least one antimicrobial prior to the receipt of high-
dose daptomycin for enterococcal infections and the medi-
an time to switch to high-dose daptomycin was 4 days 
(IQR 2-6.5).  The median dose and hospital duration of 
high-dose daptomycin was 8.2 mg/kg (IQR 7.7-9.7) and 10 
days (IQR 6-15), respectively.  One hundred and sixty-
eight (68.6%) patients had doses of ≥ 8 mg/kg, 34 of these 
(13.9%) patients dosed ≥ 10 mg/kg.  Two hundred fourteen 
(87.3%) patients received daptomycin interval of every 24 
hours.  Within our whole cohort, 43.7% (107/245) patients 
were given another antibiotic concomitantly with dap-
tomycin.  The most common type of antibiotic adminis-
tered concomitantly with high-dose daptomycin was a be-
ta-lactam agent, (76.6%, 82/107) specifically a carbapenem 
(39%, 32/82).  Most of these patients were given a beta-
lactam as their infections also involved a Gram-negative 
pathogen (62.6%, 67/107) along with the enterococcus.   
The organism isolated in 245 patients were E. faecium, 
E. faecalis, and Enterococcus spp., in 175 (71.4%), 49 
(20%), and 21 (8.6%), respectively.  Of these enterococci, 
204 (83.3%) were vancomycin-resistant according to insti-
tutional automated MIC testing methods. Minimum inhibi-
tory concentration (MIC) of vancomycin is displayed in 
Table 2.  One hundred fifty-five (63.3%) isolates had dap-
tomycin susceptibility available from the medical charts.  
The MIC that inhibited growth of 50% (MIC50) and 90% 
(MIC90) of baseline enterococci isolates for daptomycin 
were 2 mg/L and 4 mg/L, respectively (see Table 2 for the 
frequency and distribution of institutional daptomycin 
MICs).  Seventy-five enterococcal strains were recovered  
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Figure 1. Clinical outcome proportion per enterococci species. 
Frequency of clinical success for E. faecium, E. faecalis, and Enterococcus spp. were 85.6%, 95.7%, and 94.7%, respectively. 
 
Figure 2. Clinical success stratified by daptomycin minimum inhibitory concentration. 
DAP = daptomycin; Frequency of clinical success for daptomycin minimum inhibitory concentration for 0.25, 0.38, 0.5, 1.0, 1.5, 2, 3, 4, 8 
mg/L were 100%, 100%, 100%, 93%, 85%, 84%, 91%, 81% and 0%, respectively. 
 
for extended microbiologic assessment with BMD and 
Etest for vancomycin and daptomycin susceptibility.  Thir-
ty-seven (49.3%) isolates were E. faecium, 29 (38.7%) 
were E. faecalis, and 9 (12%) were Enterococcus spp.  
Overall, 56 (74.6%) were VRE confirmed by both BMD  
and Etest.  The MIC50 and MIC90 for these 75 enterococci 
isolates for daptomycin by both BMD and Etest were 1 
mg/L and 2 mg/L, respectively.  The median daptomycin 
MIC for E. faecium by BMD and Etest were 2 mg/L (range 
of 0.25-4 mg/L) and 2 mg/L (range of 0.5-4 mg/L), respec-
tively.  E. faecalis median daptomycin MIC by BMD and 
Etest were 0.5 mg/L (range 0.125-2 mg/L) and 1 mg/L 
(range 0.25-3 mg/L), respectively. The median daptomycin 
MIC for Enterococcus spp. by BMD and Etest were 1 
mg/L (range 0.5-2 mg/L) and 1.5 mg/L (range 0.5-3 mg/L), 
respectively.  Thirty-one enterococci isolates had a report-
ed daptomycin MIC from the institution and a correlation 
of daptomycin BMD and Etest method was observed with 
Spearman’s rank correlation coefficient of 0.53 (p = 0.002) 
and 0.42 (p = 0.019), respectively. 
Two hundred and eighteen (89%) patients were clini-
cally evaluable; with 147 (67.4%) patients were cured and 
46 (21.1%) improved from their enterococcal infection.  
Clinical success(21, 22) was evaluated as the combined 
total of patients cured or improved; overall a total of 193 
(88.5%) patients achieved clinical success.  Proportion of 
clinical success by enterococci species is described in Fig-
ure 1, which displays a difference in clinical success for E. 
faecium versus E. faecalis.  One hundred thirty-seven 
(62.8%) patients had clinical outcomes available with dap-
tomycin susceptibility.  Stratification by daptomycin MIC 
is displayed in Figure 2, and demonstrated the variability in 
outcome as it relates to MIC.  Clinical success did not dif-
fer between daptomycin MIC groups with 53.4% and 46.6% 
for MIC ≤ 2 mg/L and MIC > 2 mg/L group respectively (p 
= 0.371).  One hundred and ninety-one (78%) patients 
were microbiologically evaluable since follow-up cultures 
were available, and overall 177/191 (92.7%) patients had 
microbiological eradication with high-dose daptomycin.  
Of the microbiologically available patients, 32/33 (97%)  
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Figure 3. Maximum observed creatine phosphokinase level. 
CPK = creatine phosphokinase; HD DAP = high dose daptomycin 
 
with E. faecalis, 134/147 (91.2%) with E. faecium, and 
11/11 (100%) with Enterococcus spp. had microbiological 
eradication. The median time to clearance of blood cultures 
was 3 days (IQR 2-5).  Of the 14 patients with microbio-
logic persistence, 10 (71.4%) were complicated bacteremia, 
sites of infection included: 1 (7.1%) osteomyelitis, 2 
(14.7%) skin and wound infection, 5 (35.7%) intra-
abdominal infection, 4 (28.6%) IV catheter related infec-
tion, 1 (7.1%) left ventricular assist device and 1 (7.1%) 
right-sided infective endocarditis.  Median duration of fe-
ver and leukocytosis during the enterococcal infection was 
3 days (IQR 1-6) and 7 days (IQR 2-14.3), respectively.  
Median ICU length of stay and total length of stay was 8 
days (IQR 3-15) and 22 days (IQR 13-39), respectively.  
Among the patients admitted to the ICU 85/125 (68%) 
were mechanically ventilated with median duration of me-
chanical ventilation was 8 days (IQR 2-14).  All-cause in-
hospital mortality was 19.6% (48/245) of patients.  Of 
these 48 patients, 42/48 (87.5%) had E. faecium isolated, 
46/48 (95.8%) had VRE isolated, and 41/48 (85.4%) had 
BSI.  Forty-one of the expired patients were microbiologi-
cally evaluable and 34/41 (82.9%) were microbiologically 
eradicated. The 30-day all cause mortality rate was 26.5% 
(50 patients) for the 189 patients (77.1%) who had follow-
up. 
Overall, no patients experienced an adverse event at-
tributed to high-dose daptomycin therapy. Baseline and 
subsequent CPK levels were available for 220 (89.8%) 
patients.  Fifty-four (22%) were receiving concomitant 3-
hydroxy-3methylglutaryl-coenzyme A reductase inhibitors 
(statins) and 20 (8.2%) patients were placed on intramus-
cular injections while on high-dose daptomycin.  Seven 
(3.2%) patients had CPK elevations from baseline; one 
patient had a baseline CPK ≥ ULN that increased to 5x 
ULN while on high-dose daptomycin and the remaining six 
patients had a baseline CPK ≤ ULN that increased to 3x 
ULN while on high-dose daptomycin.  A distribution of 
observed maximum CPK level after 3 days of high dose 
daptomycin stratified by daptomycin dosages is character-
ized in Figure 3.  No apparent relationship between high-
dose daptomycin and maximum CPK level was observed 
(Spearman’s rank correlation coefficient of 0.07, p = 0.28).  
Of interest, one patient who had a baseline CPK level of ≥ 
10x ULN saw a decrease in CPK to a level of 753 IU/L 
after 6 days of high-dose daptomycin (10.4 mg/kg every 24 
hours) and remained asymptomatic throughout therapy.  
There was no reported myopathy or myositis while on 
high-dose daptomycin.  All patients with CPK levels ≥ 5x 
ULN were asymptomatic and no patients were reported to 
have a CPK level increase to ≥ 10x ULN while on dap-
tomycin.  High-dose daptomycin was observed in one pa-
tient case to be safe up to 15.7 mg/kg (every 24 hours) for 
up to 14 days when used to treat VRE faecium complicated 
bacteremia from an abdominal source; the highest CPK 
level observed was 383 IU/L.  The highest observed patient 
weight was 164 kg, who received daptomycin 8.2 mg/kg 
(every 24 hours) for 12 days and with no observation of 
CPK elevation for the treatment of VRE faecium infective 
endocarditis with the highest CPK level observed at 26 
IU/L. 
Daptomycin nonsusceptibility was identified in six pa-
tients by the institution’s automated MIC testing system or 
by Etest methodology; one isolate was found to be nonsus-
ceptible in the initial blood culture and five strains devel-
oped nonsusceptibility during daptomycin therapy.  One 
patient had a VRE faecium initial daptomycin MIC of 8  
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Table 3 
Patients with VRE faecitum infections that developed nonsusceptibility to daptomycin. 




Days to MIC change 
while on HD-DAP 
Subsequent 
DAP MIC (mg/L) 
Outcome 
Complicated IV catheter 
related BSI 
8.2 2* 16 > 4* Added gentamicin but expired 
during hospitalization 
Complicated IV catheter 
related BSI 
8.2 4* 13 > 4* Discharged with HD-DAP with 
gentamicin  
DNS identified after D/C 
N/A for 30 days F/U 
Complicated Prosthetic 
Device related BSI 
6.17 1* 8 > 4* Switched to LIN and cleared 
BSI  
N/A for 30 days F/U 
Complicated BSI from 
skin/wound 
10.1 4# 58 32# Switched to Quinupristin/ 
Dalfopristin and cleared BSI 
Alive at 30 days F/U  
Intra-abdominal  7.5 2# 13 24# Switched to LIN and not other 
follow-up cultures 
Alive at 30 days F/U 
HD-DAP = high-dose daptomycin; DAP = daptomycin; MIC = minimum inhibitory concentration; IV = intravenous; BSI = bloodstream infection; 
DNS = daptomycin nonsusceptibility; D/C = discharged from hospital; LIN = linezolid; N/A = not available; * = MIC identified by automated 
testing method from institution; # = MIC identified by Etest testing methodology
mg/L treated with vancomycin for three days and switched 
to high-dose daptomycin (7.94 mg/kg every 24 hours) for 
right-sided infective endocarditis once VRE was identified. 
Daptomycin was later switched to linezolid after seven 
days of high-dose daptomycin therapy and blood cultures  
cleared after three days of linezolid therapy (linezolid MIC 
of 2 mg/L).  Five (2%) patients developed nonsusceptibil-
ity to daptomycin, with all isolates being VRE. faecium.  
These five patients were treated with high-dose daptomy-
cin and description of infection, daptomycin dosages, MIC 
data, and outcome is described in Table 3.  None of these 
patients were given a beta-lactam concomitantly with high-
dose daptomycin. 
DISCUSSION 
This study is the largest evaluation of a cohort of patients 
treated with high-dose daptomycin for enterococcal infec-
tions.  Our patient population demographics were very 
similar to prior studies evaluating enterococcal infections, 
specifically with VRE, in parameters such as ICU admis-
sion, previous vancomycin use, mechanical ventilation, 
and malignancy(30, 31).  Within our cohort, 91 (37.1%) 
patients were switched to high-dose daptomycin following 
prior therapy with in vitro activity (e.g. linezolid for VRE 
or vancomycin for vancomycin-susceptible enterococci); 
82 (33.5%) were administered high-dose daptomycin as a 
second-line agent and 9 (3.7%) were provided high dose 
daptomycin as a third-line agent.  The majority was initial-
ly treated with high-dose daptomycin for enterococcal in-
fections that was associated with a high frequency of clini-
cal success similar to previous literature regarding the use 
of high-dose daptomycin(20, 21).  A subgroup analysis of 
our data revealed that enterococcal BSI patients had a 
higher percentage of severe complicated infections such as 
infective endocarditis and intra-abdominal infections com-
pared to previous publications(22, 24).  We noted that a 
higher percentage of patients with enterococcal BSI tended 
to have comorbid conditions such as transplantation, diabe-
tes and liver disease (data not shown).  We also found that 
more patients received daptomycin in the ICU compared to 
the Cubicin® Outcomes Registry and Experience (CORE) 
study (53.2% vs. 27%) for treatment of enterococcal bacte-
remia(22).  Our data had similar clinical success frequen-
cies compared to the CORE data(22); in contrast, a higher 
frequency of microbiological cure (92.7%, 152/164) was 
observed compared to previous literature(21, 24).  This 
improved outcome suggests a higher dose of daptomycin 
may be a favorable treatment option for complicated enter-
ococcal BSI since the median dose of daptomycin for en-
terococcal BSI in our patients were higher compared to the 
CORE data, 8.2 mg/kg (range 6.02-15.70 mg/kg) and 6 
mg/kg (range 2.9-14.8 mg/kg), respectively. 
The treatment options for VRE BSI are limited.  Alt-
hough FDA approved for the treatment of VRE infections, 
including concomitant BSI due to E. faecium, linezolid is 
bacteriostatic(6).  A retrospective cohort analysis by Crank 
and colleagues compared linezolid to daptomycin for VRE 
BSI and found no statistical difference in mortality, 29.4% 
vs. 46.3%, p = 0.10(32).  The mortality was higher in the 
daptomycin group by Crank and colleagues but there were 
significant differences between the two treatments groups 
in baseline characteristics with a higher proportion of the 
daptomycin group having shock and have received previ-
ous treatment.  Our enterococcal BSI hospital mortality 
was 23.7% (41/173), lower compared to Crank and col-
leagues retrospective cohort study.  In addition, a retro-
spective study by Mave and colleagues compared the clini-
cal outcomes of linezolid and daptomycin and found no 
significant difference between the two groups(33).   Our 
study’s characteristics were similar to Mave and colleagues’ 
retrospective study (not shown) along with the frequency 
of mortality in VRE BSI, 27% (40/148) and 26.7% (8/30), 
respectively.  After reviewing all of these factors, the fre-
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quency of microbiological cure was much higher in our 
study compared to Mave and colleagues for the treatment 
of VRE BSI with daptomycin.  This may suggest that high-
dose daptomycin may be a favorable option for the treat-
ment of VRE BSI. 
Combination therapy of daptomycin and another anti-
biotic such as rifampin, gentamicin, linezolid, or a beta-
lactam may also be an option for enterococcal infections, 
especially for severe or refractory VRE BSI(34, 35).  Of 
interest, within our cohort of patients that were concomi-
tantly administered a beta-lactam, 89.1% (41/46) of the 
VRE BSI patients had clinical success similar to recent 
publication(36).  This may be of interest, from a recent 
data describing a positive outcome in beta-lactams and 
daptomycin used in the clearance of refractory VRE bacte-
remia.  It is unknown if the standard dose of daptomycin (6 
mg/kg) in combination with a beta-lactam maybe a viable 
option compared to high-dose daptomycin but further re-
search is necessary to evaluate the impact of concomitant 
beta-lactams with daptomycin especially in serious VRE 
infections and with various dosages of daptomycin (low vs. 
high-dose).  Our data may show a high frequency of suc-
cess but this was not an a priori focus for data collection.  
Even if these enterococci are resistant to beta-lactams in-
cluding ampicillin, beta-lactams appears to enhance the 
activity of daptomycin through reduction in net positive 
surface charge(35). 
Overall, all patients tolerated high-dose daptomycin 
and no adverse events were reported while on daptomycin.  
CPK levels were obtained in approximately 90% of our 
patient population.  Prior studies have reported high dosag-
es of daptomycin to be safe with no elevations of CPK 
concentrations while on therapy(23, 37), although others 
have reported CPK elevations that led to the discontinua-
tion of high-dose daptomycin due to musculoskeletal 
symptoms or related adverse events(20, 38, 39).   Recent 
data have reported that high-dose daptomycin may elevate 
CPK level at an incidence of 2.5-8.3%(39) but no patients 
reported symptoms consistent with muscle toxicity(21, 40).  
This finding is consistent with our data, demonstrating 
high-dose daptomycin to be well tolerated.  Within our 
study, the highest daptomycin dose given to a patient was 
15.7 mg/kg and the longest duration of therapy given to 
another patient was 128 days; these two patients tolerated 
high-dose daptomycin for a prolonged duration, remained 
asymptomatic and neither experienced a CPK elevation.  
Additional study supports that high-dose daptomycin may 
be tolerable and does not necessarily have a dose or dura-
tion-dependent relationship to CPK elevation(41). 
Our study is a multicenter observational investigation 
that incorporates a diverse cohort of adult patients across 
the United States; however this retrospective design does 
have some limitations.  Our study design is descriptive and 
therefore we were not able to compare our results with 
those derived from patients receiving lower dosages of 
daptomycin or another anti-VRE agent such as linezolid. In 
addition, not all patients had CPK levels collected to eval-
uate for potential elevation although it is interesting to note 
that all patients evaluated were asymptomatic and no pa-
tient discontinued therapy while on high-dose daptomycin.  
On account of this study’s retrospective nature, it is diffi-
cult to detect other possible adverse events and there could 
have been adverse events that were not attributed to dap-
tomycin. 
In conclusion, these results suggest that high-dose 
daptomycin may be an option for the treatment of entero-
coccal infections, including VRE BSI.  This study also 
suggests that high-dose daptomycin may provide a high 
frequency of clinical success along with microbiological 
eradication, despite significant comorbid conditions.  Since 
high-dose daptomycin appears to be a safe, effective, and 
tolerable treatment option, further prospective studies of 
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